Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.

Chuang P, Langone AJ
Am J Ther. 2007 14 (5): 438-41

PMID: 17890931 · DOI:10.1097/01.mjt.0000209693.83065.a6

Hyperlipidemia is common after renal transplantation. On the basis of current lipid guidelines, the majority of renal transplant recipients should have plasma low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL. Even with statin (HMG-CoA [3-hydroxy-3-methylglutaryl CoA] reductase inhibitor) therapy, a significant number of renal transplant recipients have LDL-C levels >100 mg/dL. We report that ezetimibe, a novel inhibitor of intestinal cholesterol absorption, was well tolerated and effectively reduced the LDL-C level to <100 mg/dL in our cohort of renal transplant recipients with persistently elevated LDL-C levels during treatment with maximally tolerated statin medications.

MeSH Terms (16)

Adult Aged Anticholesteremic Agents Azetidines Cholesterol, LDL Ezetimibe Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemias Kidney Transplantation Male Middle Aged Practice Guidelines as Topic Retrospective Studies Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities:

Links